U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.36
    -0.43 (-1.90%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.16%)
     
  • BTC-USD

    47,333.41
    -1,030.11 (-2.13%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Smiths Group Divests Its Medical Division To ICU Medical In $2.4B Deal

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ICU Medical Inc (NASDAQ: ICUI) has agreed to acquire Smiths Group plc's Medical division in a transaction that will create an IV therapy company and simplify customer workflow.

  • The Smiths Medical business includes syringe & ambulatory infusion devices, vascular access, and vital care products.

  • When combined with ICU Medical's existing businesses, the combined entity will generate estimated pro forma revenues of approximately $2.5 billion.

  • Smiths will receive 2.5 million newly issued ICU Medical shares, currently valued at approximately $500 million, and $1.85 billion in cash.

  • Smiths will own approximately 10% of ICU Medical. It is also eligible to receive a contingent earn-out consideration of $100 million in cash.

  • The transaction is expected to close in 1H of 2022. In addition, at closing, a Smiths designee will be appointed to the ICU Medical board of directors.

  • Price Action: ICUI stock closed 1.58% higher at $205.98 on Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.